Compare Amylx Pharmaceuticals Inc (AMLX) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Canadian National Railway Co. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Canadian National Railway Co. trades at $124.96 (market cap $75.28B). The key difference: Canadian National Railway Co. is far larger — about 38× Amylx Pharmaceuticals Inc's market cap, and Canadian National Railway Co. pays a 2.07% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CNI | |
|---|---|---|
Market Cap | $1.98B | $75.28B |
Sector | Health | Industrials |
52-Week High | $18.70 | $124.40 |
52-Week Low | $7.64 | $90.91 |
Enterprise Value | $1.70B | $90.74B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
CNI trades at $124.40, up 0.05% with a bullish technical outlook. The company reported Q1 2026 EPS of $1.31, meeting expectations, and maintains strong profitability with a 27.23% net margin. Recent news highlights record propane shipments and a new potash transport agreement with BHP, signaling operational strength. Analyst consensus is a Buy with a $143.71 price target, implying 15.5% upside from current levels.
The stock presents a solid long-term opportunity driven by operational efficiency and strategic growth initiatives, though elevated valuation multiples and rising debt levels warrant caution. Near-term performance hinges on Q2 2026 earnings due July 24, 2026, with market sentiment leaning positive amid sustainable dividend payments and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
